648 results on '"Friberg, Lena E."'
Search Results
202. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
203. Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
204. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
205. A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan
206. Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics
207. Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
208. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
209. Population Pharmacokinetics of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients: New Initial Dosage Suggestions and a Model-Based Dosage Adjustment Tool
210. Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates
211. A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants
212. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS
213. A tool for neutrophil guided dose adaptation in chemotherapy
214. Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake
215. Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia
216. Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.
217. Reply to Dr. Mégarbane et al. regarding “Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose”
218. Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828
219. Dr. Hartmut Derendorf, PhD, a world‐renowned expert in pharmacokinetics and pharmacometrics (1953–2020).
220. In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients
221. Characterizing variability in warfarin dose requirements in children using modelling and simulation.
222. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
223. Predictions of In Vivo Prolactin Levels from In Vitro Ki Values of D2 Receptor Antagonists Using an Agonist-Antagonist Interaction Model.
224. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
225. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
226. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
227. Reply to Wilson et al.
228. Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
229. Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel.
230. Integration of individual preclinical and clinical anti‐infective PKPD data to predict clinical study outcomes.
231. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety
232. Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration
233. Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants
234. Predicting In VitroAntibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model
235. Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
236. Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework.
237. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib.
238. Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coliExposed to Cefuroxime
239. Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosain Automated Time-Lapse Microscopy and Static Time-Kill Experiments
240. Multistate modeling for survival analysis in critically ill patients treated with meropenem.
241. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis.
242. Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions.
243. Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.
244. A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology.
245. A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer.
246. Colistin Is Extensively Lost during Standard In VitroExperimental Conditions
247. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosaBiofilm Lung Infection in Wistar Rats
248. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.
249. Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia.
250. Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.